UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

Nature, 2003-09, Vol.425 (6956), p.407-410

2003

Volltextzugriff (PDF)

Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures

Cancer research (Chicago, Ill.), 1990-11, Vol.50 (21), p.6959-6965

1990

Volltextzugriff (PDF)

Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity

Journal of medicinal chemistry, 2007-06, Vol.50 (12), p.2767-2778

2007

Volltextzugriff (PDF)

Tumor necrosis factor expression during mouse hepatitis virus-induced demyelinating encephalomyelitis

Journal of Virology, 1995-09, Vol.69 (9), p.5898-5903

1995

Volltextzugriff (PDF)

Abstract P6-04-12: Novel selective estrogen receptors degraders regress tumors in pre-clinical models of endocrine-resistant breast cancer

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P6-P6-04-12

2012

Volltextzugriff (PDF)

Differential effects of flanking residues on presentation of epitopes from chimeric peptides

Journal of Virology, 1994-08, Vol.68 (8), p.5306-5310

1994

Volltextzugriff (PDF)

Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90

Journal of medicinal chemistry, 2006-01, Vol.49 (2), p.817-828

2006

Volltextzugriff (PDF)

Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction

The Journal of immunology (1950), 1994-06, Vol.152 (12), p.5603-5612

1994

Volltextzugriff (PDF)

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

Cancer research (Chicago, Ill.), 2012-03, Vol.72 (6), p.1494-1503

2012

Volltextzugriff (PDF)

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90

Molecular cancer therapeutics, 2009-04, Vol.8 (4), p.921-929

2009

Volltextzugriff (PDF)

Discovery of Potent Myeloid Cell Leukemia‑1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer

Journal of medicinal chemistry, 2019-04, Vol.62 (8), p.3971-3988

2019

Volltextzugriff (PDF)

Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 Inhibitors

Journal of medicinal chemistry, 2023-12, Vol.66 (24), p.16783-16806

2023

Volltextzugriff (PDF)

Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core

Journal of medicinal chemistry, 2020-01, Vol.63 (2), p.656-675

2020

Volltextzugriff (PDF)

Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors

Journal of medicinal chemistry, 2024-08, Vol.67 (16), p.14370-14393

2024

Volltextzugriff (PDF)

Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models

Proceedings of the National Academy of Sciences - PNAS, 2023-01, Vol.120 (1), p.e2211297120

2023

Volltextzugriff (PDF)

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia

Cancer discovery, 2018-12, Vol.8 (12), p.1566-1581

2018

Volltextzugriff (PDF)

Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors

FEBS letters, 2017-01, Vol.591 (1), p.240-251

2017

Volltextzugriff (PDF)

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Journal of medicinal chemistry, 2015-06, Vol.58 (12), p.4888-4904

2015

Volltextzugriff (PDF)

Fragment-Based Screen of SARS-CoV‑2 Papain-like Protease (PLpro)

ACS medicinal chemistry letters, 2024-08, Vol.15 (8), p.1351-1357

2024

Volltextzugriff (PDF)

7‘-Substituted Benzothiazolothio- and Pyridinothiazolothio-Purines as Potent Heat Shock Protein 90 Inhibitors

Journal of medicinal chemistry, 2006-08, Vol.49 (17), p.5352-5362

2006

Volltextzugriff (PDF)

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer

Journal of medicinal chemistry, 2018-09, Vol.61 (17), p.7917-7928

2018

Volltextzugriff (PDF)

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

eLife, 2016-07, Vol.5

2016

Volltextzugriff (PDF)

Maximizing ER‑α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927

ACS medicinal chemistry letters, 2019-01, Vol.10 (1), p.50-55

2019

Volltextzugriff (PDF)

Discovery and Structure-Based Optimization of Potent and Selective WDR5 Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core

Journal of medicinal chemistry, 2020-01, Vol.63 (2), p.656-675

2020

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)
Tagungsberichte
(1)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures

Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity

Tumor necrosis factor expression during mouse hepatitis virus-induced demyelinating encephalomyelitis

Abstract P6-04-12: Novel selective estrogen receptors degraders regress tumors in pre-clinical models of endocrine-resistant breast cancer

Differential effects of flanking residues on presentation of epitopes from chimeric peptides

Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90

Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction

ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90

Discovery of Potent Myeloid Cell Leukemia‑1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer

Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 Inhibitors

Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core

Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors

Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models

A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia

Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Fragment-Based Screen of SARS-CoV‑2 Papain-like Protease (PLpro)

7‘-Substituted Benzothiazolothio- and Pyridinothiazolothio-Purines as Potent Heat Shock Protein 90 Inhibitors

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

Maximizing ER‑α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927

Discovery and Structure-Based Optimization of Potent and Selective WDR5 Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core

Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core

Suchergebnisse filtern